Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as XL765 (SAR245409)
XL765 · 4 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Twice-daily dosing (every 12 hours) XL765 |
| 2 | EXPERIMENTAL | Once-daily dosing XL147 |
| 3 | EXPERIMENTAL | Once-daily dosing XL765 |
| Name | Type | Description |
|---|---|---|
| XL765 (SAR245409) | DRUG | Supplied as 10-mg and/or 50-mg capsules |
| XL147 (SAR245408) | DRUG | Supplied as 100-mg, 150-mg and/or 200-mg tablets |
| Temozolomide | DRUG | Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days |
| erlotinib | DRUG | Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing |
Inclusion Criteria: 1. The subject has histologically confirmed diagnosis of primary GB for which the subject has received prior treatment, including radiation and/or chemotherapy, and will be undergoing a second surgical resection. 2. The subject has available archival tumor tissue from the time o...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
XL765 is an investigational small molecule being studied in oncology for the treatment of cancer, including glioblastoma, mixed gliomas, and other solid tumors. It has been evaluated in Phase 1 clinical trials in adults with recurrent glioblastoma, malignant gliomas, non-small cell lung cancer, and advanced solid tumors.
XL765 is being developed by Sanofi, which trades under the ticker SNY. The drug is also known as SAR245409.
XL765 is in Phase 1 clinical development. All four of its listed trials are Phase 1 studies, and all are completed. The drug is investigational and has not been approved by the FDA.
XL765 has been studied in four completed Phase 1 trials: NCT01240460 in recurrent glioblastoma, NCT00777699 in combination with erlotinib in solid tumors and non-small cell lung cancer, NCT00704080 with temozolomide in malignant gliomas, and NCT00485719 in solid tumors.
Yes, XL765 and SAR245409 are the same drug. SAR245409 is an alternative name for XL765, and both names refer to the same investigational small molecule developed by Sanofi.